Detail akcie Immunovia Rg online

Business Summary: Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Immunovia AB (publ) revenues decreased 5% to SEK229K. Net loss applicable to common stockholders increased from SEK28.5M to SEK98.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Financial expenses increase from SEK297K to SEK59.9M (expense), Financial income decrease of 100% to SEK37K (income).